Veracyte Competitors
| VCYT Stock | USD 31.52 0.00 0.00% |
Veracyte vs Adaptive Biotechnologies Correlation Overview
Weak diversification
The correlation between VCYT and ADPT is 0.33, which Macroaxis classifies as Weak diversification for the selected horizon. Used correctly, the chart helps investors judge whether adding the second position genuinely diversifies the first.
Moving against Veracyte Stock
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Veracyte's price to converge to an average value over time is called mean reversion.
Veracyte Competition Correlation Matrix
Correlation analysis between Veracyte and its competitors helps investors understand whether diversification is real or only superficial inside the same peer group. This matrix is most informative when investors want to know whether adding another peer would improve diversification, increase crowding, or leave total risk largely unchanged.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Veracyte Stock performing well and Veracyte Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Veracyte's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| KNSA | 1.81 | 0.18 | 0.08 | 0.95 | 2.50 | 3.93 | 12.32 | |||
| ZLAB | 2.18 | 0.01 | 0.00 | -0.03 | 0.00 | 6.02 | 10.90 | |||
| LEGN | 2.68 | -0.56 | 0.00 | 0.82 | 0.00 | 5.78 | 19.65 | |||
| SRRK | 2.30 | -0.01 | 0.00 | -0.06 | 0.00 | 5.12 | 14.33 | |||
| IRON | 3.02 | -0.55 | 0.00 | -1.73 | 0.00 | 4.63 | 27.84 | |||
| TARS | 1.86 | -0.21 | 0.00 | -0.30 | 0.00 | 4.43 | 12.09 | |||
| IDYA | 2.08 | -0.05 | 0.00 | -0.37 | 0.00 | 5.69 | 11.16 | |||
| APLS | 2.34 | -0.31 | 0.00 | -0.74 | 0.00 | 4.12 | 25.67 | |||
| FOLD | 1.16 | 0.63 | 2.08 | 2.59 | 0.00 | 1.01 | 30.77 | |||
| ADPT | 2.41 | -0.17 | 0.00 | -0.28 | 0.00 | 4.29 | 22.58 |
Peer Comparison: Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Veracyte financial statement analysis. It represents the amount of money remaining after all of Veracyte operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Compare Veracyte and related stocks such as Kiniksa Pharmaceuticals, Zai Lab, and Legend Biotech Corp Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KNSA | -24 M | -24 M | -24 M | -24 M | -24 M | -24 M | -24 M | -64.9 M | -103.2 M | -161.9 M | -161.4 M | -157.9 M | 183.4 M | 14.1 M | -43.2 M | 59 M | 62 M |
| ZLAB | -18 M | -18 M | -18 M | -18 M | -18 M | -18 M | -37.5 M | -50.4 M | -139.1 M | -183.4 M | -268.9 M | -704.5 M | -443.3 M | -334.6 M | -257.1 M | -175.5 M | -184.3 M |
| LEGN | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | -2.8 M | -101.6 M | -266.4 M | -403.6 M | -446.3 M | -518.3 M | -177 M | -297.6 M | -312.5 M |
| SRRK | -16.2 M | -16.2 M | -16.2 M | -16.2 M | -16.2 M | -16.2 M | -16.2 M | -25 M | -49.3 M | -49.7 M | -85 M | -131.8 M | -131.6 M | -165.8 M | -246.3 M | -377.9 M | -359 M |
| IRON | -40.8 M | -40.8 M | -40.8 M | -40.8 M | -40.8 M | -40.8 M | -40.8 M | -40.8 M | -40.8 M | -40.8 M | -40.8 M | -36 M | -46.1 M | -76.4 M | -109.4 M | -212.2 M | -201.6 M |
| TARS | -1.3 M | -1.3 M | -1.3 M | -1.3 M | -1.3 M | -1.3 M | -1.3 M | -1.3 M | -1.3 M | -4.7 M | -26.8 M | -13.8 M | -62.1 M | -135.9 M | -115.6 M | -66.4 M | -69.7 M |
| IDYA | -11.9 M | -11.9 M | -11.9 M | -11.9 M | -11.9 M | -11.9 M | -11.9 M | -11.9 M | -34.3 M | -38.4 M | -32.3 M | -47.5 M | -54.8 M | -113 M | -274.5 M | -113.7 M | -119.4 M |
| APLS | -4 M | -4 M | -4 M | -4 M | -10.8 M | -46.5 M | -27.1 M | -51 M | -127.5 M | -304.7 M | -344.9 M | -746.4 M | -652.2 M | -528.6 M | -197.9 M | 22.4 M | 23.5 M |
| FOLD | -6.8 M | -44.4 M | -48.8 M | -59.6 M | -68.9 M | -132.1 M | -200 M | -284 M | -349 M | -356.4 M | -276.9 M | -250.5 M | -236.6 M | -151.6 M | -56.1 M | -27.1 M | -28.5 M |
| ADPT | -42.8 M | -42.8 M | -42.8 M | -42.8 M | -42.8 M | -42.8 M | -42.8 M | -42.8 M | -46.4 M | -68.6 M | -146.2 M | -207.3 M | -200.2 M | -225.2 M | -159.5 M | -59.5 M | -62.5 M |
Veracyte Competitive Analysis
Within its peer group that includes Kiniksa Pharmaceuticals, Zai Lab, and Legend Biotech, Veracyte stands out in several ways. The company commands a 2.46 B market valuation built on 517.1 M in annual revenue. Profitability stands at a 12.83% net margin with return on equity reaching 5.34%. Kiniksa Pharmaceuticals leads with 11.73% return on equity versus 5.34% for Veracyte. On the bottom line, Veracyte retains 12.83% while Zai Lab manages -38.15%. Revenue tilts toward Legend Biotech at 1.03 B compared with 517.1 M.| Better Than Average | Worse Than Peers | View Performance Chart |
Peer Performance Charts
How to Analyze Veracyte Against Peers
Veracyte's peer analysis compares Veracyte with related companies to put valuation, quality, and risk metrics in context. This helps determine whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:- Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
- Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
- Check valuation dispersion: Review whether Veracyte trades at a premium or discount versus peers and why.
- Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
- Document the thesis: Record where Veracyte leads or lags and what catalysts could close or widen the gap.